SCHEMBL166680

SCHEMBL166680

Cc1cc(Nc2nc(S(=O)(=O)c3ccc(F)cc3)cc3ccccc23)nn1C(=O)OC(C)(C)C

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 3/20 0.38
NR1H3 Q13133 1/20 0.38
HTR6 P50406 1/20 0.36
MMP13 P45452 2/20 0.35
MEN1 O00255 1/20 0.34
TP53 P04637 1/20 0.34
MAPT P10636 1/20 0.34
ALOX15 P16050 1/20 0.34
KMT2A Q03164 1/20 0.34
GPR119 Q8TDV5 2/20 0.34
RORC P51449 4/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2C9 P11712 1/20 0.33
CNR1 P21554 1/20 0.33
CNR2 P34972 1/20 0.33
GNRHR P30968 1/20 0.33
P2RX7 Q99572 1/20 0.33
MMP2 P08253 1/20 0.33
POLB P06746 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL164233 0.82 MAPT (0.34) NR1H2NR1H3MEN1TP53MAPT
SCHEMBL165550 0.82 MAPT (0.37) NR1H2NR1H3MEN1TP53MAPT
SCHEMBL174448 0.74 HTR6 (0.38) HTR6MEN1MAPTKMT2ACYP3A4
SCHEMBL177328 0.72 AURKA (0.52) CYP3A4CYP2C9
SCHEMBL254830 0.72 AKR1B1 (0.38) HTR6MEN1MAPTKMT2A
SCHEMBL159667 0.71 JAK2 (0.43) HTR6POLB
SCHEMBL15366464 0.71 JAK2 (0.38) HTR6
SCHEMBL173272 0.70 AKR1B1 (0.39) CYP3A4CYP2C9
SCHEMBL178180 0.70 AURKA (0.40) CYP3A4CYP2C9
SCHEMBL174447 0.68 CHEK1 (0.37) HTR6MEN1MAPTKMT2AMMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2663553-B1 QUINOLINE AND ISOQUINOLINE DERIVATIVES FOR USE AS JAK MODULATORS AMBIT BIOSCIENCES CORP (US) 2015-08-26 EP disclosed
EP-2663553-A2 QUINOLINE AND ISOQUINOLINE COMPOUNDS AND METHODS OF USE THEREOF Ambit Biosciences Corporation (US) 2013-11-20 EP disclosed
US-20130296363-A1 QUINOLINE AND ISOQUINOLINE DERIVATIVES FOR USE AS JAK MODULATORS AMBIT BIOSCIENCES CORPORATION (US) 2013-11-07 US disclosed
WO-2012030944-A2 QUINOLINE AND ISOQUINOLINE COMPOUNDS AND METHODS OF USE THEREOF AMBIT BIOSCIENCES CORPORATION (US) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130296363-A1 QUINOLINE AND ISOQUINOLINE DERIVATIVES FOR USE AS JAK MODULATORS JAK3, JAK2, JAK1 NR1H2 2686/4885NR1H3 2775/4885HTR6 1616/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.